logo
Takeda’sZasocitinibSignificantlyOutperformsDeucravacitinibinHead-to-HeadPhase3PsoriasisStudy,PromisingtoRedefineOralTreatmentExpectations
===2026/6/12 9:58:16===

Christopher O’Reilly
takeda.ir.contact@takeda.com

Media Relations
Tsuyoshi Tada (Tokyo)
tsuyoshi.tada@takeda.com

Jennifer Henesey (Boston)
Jennifer.Henesey@takeda.com





=*=*=*=*=*=
当前为第21/21页
上一页-
=*=*=*=*=*=
返回新闻列表
返回网站首页